New drug cocktail aims to boost survival in colorectal cancer liver spread
NCT ID NCT06280495
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two drugs (serplulimab and bevacizumab) to standard chemotherapy improves outcomes for people with colorectal cancer that has spread to the liver and can be surgically removed. The trial involves 156 adults aged 18-75 with specific genetic types (RAS/BRAF wild-type, pMMR/MSS). The goal is to see if the combination helps the immune system fight the cancer better and improves long-term survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?